O	0	4	EPOX	EPOX	NN	B-NP
O	5	13	inhibits	inhibit	VBZ	B-VP
O	14	26	angiogenesis	angiogenesis	NN	B-NP
O	27	29	by	by	IN	B-PP
O	30	41	degradation	degradation	NN	B-NP
O	42	44	of	of	IN	B-PP
O	45	48	Mcl	Mcl	NN	B-NP
O	48	49	-	-	HYPH	B-NP
O	49	50	1	1	CD	I-NP
O	51	58	through	through	IN	B-PP
O	59	62	ERK	ERK	NN	B-NP
O	63	75	inactivation	inactivation	NN	I-NP
O	75	76	.	.	.	O

O	77	84	PURPOSE	PURPOSE	NN	B-NP
O	84	85	:	:	:	O
O	86	100	Antiangiogenic	Antiangiogenic	JJ	B-NP
O	101	108	therapy	therapy	NN	I-NP
O	109	111	is	be	VBZ	B-VP
O	112	122	considered	consider	VBN	I-VP
O	123	125	as	as	IN	B-PP
O	126	128	an	an	DT	B-NP
O	129	138	effective	effective	JJ	I-NP
O	139	147	strategy	strategy	NN	I-NP
O	148	151	for	for	IN	B-PP
O	152	163	controlling	control	VBG	B-VP
O	164	167	the	the	DT	B-NP
O	168	174	growth	growth	NN	I-NP
O	175	178	and	and	CC	I-NP
O	179	189	metastasis	metastasis	NN	I-NP
O	190	192	of	of	IN	B-PP
B-Cancer	193	199	tumors	tumor	NNS	B-NP
O	199	200	.	.	.	O

O	201	206	Among	Among	IN	B-PP
O	207	208	a	a	DT	B-NP
O	209	215	myriad	myriad	NN	I-NP
O	216	218	of	of	IN	B-PP
O	219	229	biological	biological	JJ	B-NP
O	230	240	activities	activity	NNS	I-NP
O	241	250	described	describe	VBN	B-VP
O	251	254	for	for	IN	B-PP
O	255	263	xanthone	xanthone	NN	B-NP
O	264	275	derivatives	derivative	NNS	I-NP
O	275	276	,	,	,	O
O	277	280	the	the	DT	B-NP
B-Cancer	281	291	anticancer	anticancer	JJ	I-NP
O	292	300	activity	activity	NN	I-NP
O	301	303	is	be	VBZ	B-VP
O	304	309	quite	quite	RB	B-ADJP
O	310	320	remarkable	remarkable	JJ	I-ADJP
O	320	321	,	,	,	O
O	322	325	but	but	CC	O
O	326	329	the	the	DT	B-NP
O	330	339	molecular	molecular	JJ	I-NP
O	340	349	mechanism	mechanism	NN	I-NP
O	350	352	is	be	VBZ	B-VP
O	353	356	not	not	RB	I-VP
O	357	364	clearly	clearly	RB	I-VP
O	365	373	resolved	resolve	VBN	I-VP
O	373	374	.	.	.	O

O	375	377	In	In	IN	B-PP
O	378	381	the	the	DT	B-NP
O	382	389	present	present	JJ	I-NP
O	390	395	study	study	NN	I-NP
O	395	396	,	,	,	O
O	397	399	we	we	PRP	B-NP
O	400	412	investigated	investigate	VBD	B-VP
O	413	416	the	the	DT	B-NP
O	417	431	antiangiogenic	antiangiogenic	JJ	I-NP
O	432	441	mechanism	mechanism	NN	I-NP
O	442	444	of	of	IN	B-PP
O	445	446	3	3	CD	B-NP
O	446	447	,	,	,	I-NP
O	447	448	6	6	CD	I-NP
O	448	449	-	-	HYPH	I-NP
O	449	451	di	di	NN	I-NP
O	451	452	(	(	(	O
O	452	453	2	2	CD	B-NP
O	453	454	,	,	,	O
O	454	455	3	3	CD	B-NP
O	455	456	-	-	HYPH	I-NP
O	456	468	epoxypropoxy	epoxypropoxy	NN	I-NP
O	468	469	)	)	)	O
O	469	477	xanthone	xanthone	NN	B-NP
O	478	479	(	(	(	O
O	479	483	EPOX	EPOX	NN	B-NP
O	483	484	)	)	)	O
O	484	485	,	,	,	O
O	486	487	a	a	DT	B-NP
O	488	493	novel	novel	JJ	I-NP
O	494	497	Mcl	Mcl	NNP	I-NP
O	497	498	-	-	HYPH	I-NP
O	498	499	1	1	CD	I-NP
O	500	509	targeting	target	VBG	I-NP
O	510	514	drug	drug	NN	I-NP
O	514	515	.	.	.	O

O	516	528	EXPERIMENTAL	EXPERIMENTAL	JJ	B-NP
O	529	535	DESIGN	DESIGN	NN	I-NP
O	535	536	:	:	:	O
O	537	539	To	To	TO	B-VP
O	540	548	evaluate	evaluate	VB	I-VP
O	549	552	the	the	DT	B-NP
O	553	567	antiangiogenic	antiangiogenic	JJ	I-NP
O	568	576	activity	activity	NN	I-NP
O	577	579	of	of	IN	B-PP
O	580	584	EPOX	EPOX	NN	B-NP
O	584	585	,	,	,	O
O	586	588	we	we	PRP	B-NP
O	589	592	did	do	VBD	B-VP
B-Cell	593	597	cell	cell	NN	B-NP
O	598	607	viability	viability	NN	I-NP
O	607	608	,	,	,	O
B-Cell	609	613	cell	cell	NN	B-NP
O	614	619	cycle	cycle	NN	I-NP
O	619	620	,	,	,	O
B-Tissue	621	625	tube	tube	NN	B-NP
O	626	635	formation	formation	NN	I-NP
O	636	641	assay	assay	NN	I-NP
O	642	644	in	in	FW	B-ADVP
O	645	650	vitro	vitro	FW	I-ADVP
O	650	651	,	,	,	O
O	652	655	and	and	CC	O
O	656	664	Matrigel	Matrigel	NNP	B-NP
O	665	669	plug	plug	NN	I-NP
O	670	675	assay	assay	NN	I-NP
O	676	678	in	in	FW	B-ADVP
O	679	683	vivo	vivo	FW	I-ADVP
O	683	684	.	.	.	O

O	685	687	To	To	TO	B-VP
O	688	696	evaluate	evaluate	VB	I-VP
O	697	700	the	the	DT	B-NP
O	701	707	effect	effect	NN	I-NP
O	708	710	of	of	IN	B-PP
O	711	715	EPOX	EPOX	NN	B-NP
O	716	718	on	on	IN	B-PP
O	719	722	the	the	DT	B-NP
B-Cell	723	734	endothelial	endothelial	JJ	I-NP
O	735	744	signaling	signaling	NN	I-NP
O	745	752	pathway	pathway	NN	I-NP
O	752	753	,	,	,	O
O	754	756	we	we	PRP	B-NP
O	757	760	did	do	VBD	B-VP
O	761	775	immunoblotting	immunoblotting	NN	B-NP
O	775	776	,	,	,	O
O	777	796	immunoprecipitation	immunoprecipitation	NN	B-NP
O	796	797	,	,	,	O
O	798	801	and	and	CC	O
O	802	820	immunofluorescence	immunofluorescence	NN	B-NP
O	821	829	analysis	analysis	NN	I-NP
O	829	830	.	.	.	O

B-Immaterial_anatomical_entity	831	844	Intracellular	Intracellular	JJ	B-NP
O	845	856	glutathione	glutathione	NN	I-NP
O	857	863	levels	level	NNS	I-NP
O	864	868	were	be	VBD	B-VP
O	869	879	determined	determine	VBN	I-VP
O	880	884	with	with	IN	B-PP
O	885	888	the	the	DT	B-NP
O	889	892	use	use	NN	I-NP
O	893	895	of	of	IN	B-PP
O	896	912	monochlorobimane	monochlorobimane	NN	B-NP
O	912	913	,	,	,	O
O	914	915	a	a	DT	B-NP
O	916	927	glutathione	glutathione	NN	I-NP
O	927	928	-	-	HYPH	B-NP
O	928	936	specific	specific	JJ	I-NP
O	937	942	probe	probe	NN	I-NP
O	942	943	.	.	.	O

O	944	951	RESULTS	RESULTS	NNS	B-NP
O	951	952	:	:	:	O
O	953	957	EPOX	EPOX	NN	B-NP
O	958	965	induced	induce	VBD	B-VP
B-Cell	966	977	endothelial	endothelial	JJ	B-NP
I-Cell	978	982	cell	cell	NN	I-NP
O	983	992	apoptosis	apoptosis	NN	I-NP
O	993	995	in	in	IN	B-PP
O	996	1007	association	association	NN	B-NP
O	1008	1012	with	with	IN	B-PP
O	1013	1023	proteasome	proteasome	NN	B-NP
O	1023	1024	-	-	HYPH	O
O	1024	1033	dependent	dependent	JJ	B-NP
O	1034	1037	Mcl	Mcl	NN	I-NP
O	1037	1038	-	-	HYPH	B-NP
O	1038	1039	1	1	CD	I-NP
O	1040	1051	degradation	degradation	NN	I-NP
O	1051	1052	.	.	.	O

O	1053	1057	Down	Down	RB	B-ADVP
O	1057	1058	-	-	HYPH	O
O	1058	1068	regulation	regulation	NN	B-NP
O	1069	1071	of	of	IN	B-PP
O	1072	1075	Mcl	Mcl	NN	B-NP
O	1075	1076	-	-	HYPH	B-NP
O	1076	1077	1	1	CD	I-NP
O	1078	1086	resulted	result	VBD	B-VP
O	1087	1089	in	in	IN	B-PP
O	1090	1092	an	an	DT	B-NP
O	1093	1101	increase	increase	NN	I-NP
O	1102	1104	in	in	IN	B-PP
O	1105	1108	Mcl	Mcl	NN	B-NP
O	1108	1109	-	-	HYPH	B-NP
O	1109	1110	1	1	CD	I-NP
O	1110	1111	-	-	HYPH	I-NP
O	1111	1115	free	free	JJ	I-NP
O	1116	1119	Bim	Bim	NN	I-NP
O	1119	1120	,	,	,	O
O	1121	1131	activation	activation	NN	B-NP
O	1132	1134	of	of	IN	B-PP
O	1135	1138	Bax	Bax	NN	B-NP
O	1138	1139	,	,	,	O
O	1140	1143	and	and	CC	O
O	1144	1148	then	then	RB	O
O	1149	1158	signaling	signaling	NN	B-NP
O	1159	1161	of	of	IN	B-PP
B-Cellular_component	1162	1174	mitochondria	mitochondrion	NNS	B-NP
O	1174	1175	-	-	HYPH	B-VP
O	1175	1183	mediated	mediate	VBN	B-NP
O	1184	1193	apoptosis	apoptosis	NN	I-NP
O	1193	1194	.	.	.	O

O	1195	1207	Additionally	Additionally	RB	B-ADVP
O	1207	1208	,	,	,	O
O	1209	1220	glutathione	glutathione	NN	B-NP
O	1221	1230	depletion	depletion	NN	I-NP
O	1231	1234	and	and	CC	O
O	1235	1248	extracellular	extracellular	JJ	B-NP
O	1249	1255	signal	signal	NN	I-NP
O	1255	1256	-	-	HYPH	B-NP
O	1256	1265	regulated	regulate	VBN	I-NP
O	1266	1272	kinase	kinase	NN	I-NP
O	1273	1274	(	(	(	O
O	1274	1277	ERK	ERK	NN	B-NP
O	1277	1278	)	)	)	O
O	1279	1291	inactivation	inactivation	NN	B-NP
O	1292	1295	was	be	VBD	B-VP
O	1296	1304	observed	observe	VBN	I-VP
O	1305	1307	in	in	IN	B-PP
O	1308	1312	EPOX	EPOX	NN	B-NP
O	1312	1313	-	-	HYPH	B-NP
O	1313	1320	treated	treat	VBN	I-NP
B-Cell	1321	1326	cells	cell	NNS	I-NP
O	1326	1327	.	.	.	O

O	1328	1339	Glutathione	Glutathione	NN	B-NP
O	1340	1355	supplementation	supplementation	NN	I-NP
O	1356	1364	reversed	reverse	VBD	B-VP
O	1365	1368	the	the	DT	B-NP
O	1369	1379	inhibitory	inhibitory	JJ	I-NP
O	1380	1387	effects	effect	NNS	I-NP
O	1388	1390	of	of	IN	B-PP
O	1391	1395	EPOX	EPOX	NN	B-NP
O	1396	1398	on	on	IN	B-PP
O	1399	1402	ERK	ERK	NN	B-NP
O	1402	1403	,	,	,	O
O	1404	1409	which	which	WDT	B-NP
O	1410	1419	increases	increase	VBZ	B-VP
O	1420	1423	the	the	DT	B-NP
O	1424	1439	phosphorylation	phosphorylation	NN	I-NP
O	1440	1442	of	of	IN	B-PP
O	1443	1446	Mcl	Mcl	NN	B-NP
O	1446	1447	-	-	HYPH	B-NP
O	1447	1448	1	1	CD	I-NP
O	1449	1451	at	at	IN	B-PP
O	1452	1453	T	T	NN	B-NP
O	1453	1454	(	(	(	O
O	1454	1457	163	163	CD	B-NP
O	1457	1458	.	.	.	O
O	1458	1459	)	)	)	O
O	1460	1474	Overexpression	Overexpression	NN	B-NP
O	1475	1477	of	of	IN	B-PP
O	1478	1485	mitogen	mitogen	NN	B-NP
O	1485	1486	-	-	HYPH	O
O	1486	1495	activated	activate	VBN	B-NP
O	1496	1503	protein	protein	NN	I-NP
O	1503	1504	/	/	SYM	O
O	1504	1507	ERK	ERK	NN	B-NP
O	1508	1514	kinase	kinase	NN	I-NP
O	1515	1516	(	(	(	O
O	1516	1519	MEK	MEK	NN	B-NP
O	1519	1520	)	)	)	O
O	1521	1530	partially	partially	RB	B-ADVP
O	1531	1539	reversed	reverse	VBD	B-VP
O	1540	1543	the	the	DT	B-NP
O	1544	1550	effect	effect	NN	I-NP
O	1551	1553	of	of	IN	B-PP
O	1554	1558	EPOX	EPOX	NN	B-NP
O	1559	1561	on	on	IN	B-PP
O	1562	1565	Mcl	Mcl	NN	B-NP
O	1565	1566	-	-	HYPH	B-NP
O	1566	1567	1	1	CD	I-NP
O	1568	1585	dephosphorylation	dephosphorylation	NN	I-NP
O	1585	1586	,	,	,	O
O	1587	1601	ubiquitination	ubiquitination	NN	B-NP
O	1601	1602	,	,	,	O
O	1603	1606	and	and	CC	O
O	1607	1618	degradation	degradation	NN	B-NP
O	1618	1619	,	,	,	O
O	1620	1627	further	further	RB	B-ADVP
O	1628	1639	implicating	implicate	VBG	B-VP
O	1640	1643	ERK	ERK	NN	B-NP
O	1644	1646	in	in	IN	B-PP
O	1647	1650	the	the	DT	B-NP
O	1651	1661	regulation	regulation	NN	I-NP
O	1662	1664	of	of	IN	B-PP
O	1665	1668	Mcl	Mcl	NN	B-NP
O	1668	1669	-	-	HYPH	B-NP
O	1669	1670	1	1	CD	I-NP
O	1671	1680	stability	stability	NN	I-NP
O	1680	1681	.	.	.	O

O	1682	1693	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1693	1694	:	:	:	O
O	1695	1699	This	This	DT	B-NP
O	1700	1705	study	study	NN	I-NP
O	1706	1714	provides	provide	VBZ	B-VP
O	1715	1723	evidence	evidence	NN	B-NP
O	1724	1728	that	that	IN	B-SBAR
O	1729	1733	EPOX	EPOX	NN	B-NP
O	1734	1741	induces	induce	VBZ	B-VP
O	1742	1753	glutathione	glutathione	NN	B-NP
O	1754	1763	depletion	depletion	NN	I-NP
O	1763	1764	,	,	,	O
O	1765	1768	ERK	ERK	NN	B-NP
O	1769	1781	inactivation	inactivation	NN	I-NP
O	1781	1782	,	,	,	O
O	1783	1786	and	and	CC	O
O	1787	1790	Mcl	Mcl	NN	B-NP
O	1790	1791	-	-	HYPH	B-NP
O	1791	1792	1	1	CD	I-NP
O	1793	1804	degradation	degradation	NN	I-NP
O	1805	1807	on	on	IN	B-PP
B-Cell	1808	1819	endothelial	endothelial	JJ	B-NP
I-Cell	1820	1825	cells	cell	NNS	I-NP
O	1825	1826	,	,	,	O
O	1827	1832	which	which	WDT	B-NP
O	1833	1838	leads	lead	VBZ	B-VP
O	1839	1841	to	to	TO	B-PP
O	1842	1852	inhibition	inhibition	NN	B-NP
O	1853	1855	of	of	IN	B-PP
O	1856	1868	angiogenesis	angiogenesis	NN	B-NP
O	1868	1869	.	.	.	O

O	1870	1873	Our	Our	PRP$	B-NP
O	1874	1881	results	result	NNS	I-NP
O	1882	1889	suggest	suggest	VBP	B-VP
O	1890	1894	that	that	IN	B-SBAR
O	1895	1899	EPOX	EPOX	NN	B-NP
O	1900	1902	is	be	VBZ	B-VP
O	1903	1904	a	a	DT	B-NP
O	1905	1910	novel	novel	JJ	I-NP
O	1911	1925	antiangiogenic	antiangiogenic	JJ	I-NP
O	1926	1931	agent	agent	NN	I-NP
O	1931	1932	,	,	,	O
O	1933	1939	making	make	VBG	B-VP
O	1940	1942	it	it	PRP	B-NP
O	1943	1944	a	a	DT	B-NP
O	1945	1954	promising	promising	JJ	I-NP
O	1955	1959	lead	lead	NN	I-NP
O	1960	1968	compound	compound	NN	I-NP
O	1969	1972	for	for	IN	B-PP
O	1973	1980	further	further	JJ	B-NP
O	1981	1992	development	development	NN	I-NP
O	1993	1995	in	in	IN	B-PP
O	1996	1999	the	the	DT	B-NP
O	2000	2009	treatment	treatment	NN	I-NP
O	2010	2012	of	of	IN	B-PP
O	2013	2025	angiogenesis	angiogenesis	NN	B-NP
O	2025	2026	-	-	HYPH	B-NP
O	2026	2033	related	relate	VBN	I-NP
O	2034	2045	pathologies	pathology	NNS	I-NP
O	2045	2046	.	.	.	O

